SCHEMBL19552011

SCHEMBL19552011

N#Cc1cnn(-c2ccc(NC(=O)Cc3cccc(Cl)c3)cc2S(N)(=O)=O)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 12/20 0.49
CYP2C8 P10632 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
ADRA2B P18089 1/20 0.49
HTR2C P28335 1/20 0.49
P2RX3 P56373 1/20 0.49
SLC6A3 Q01959 1/20 0.49
TMEM97 Q5BJF2 1/20 0.49
P2RX7 Q99572 1/20 0.49
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44
KCNQ2 O43526 2/20 0.43
ROCK2 O75116 2/20 0.42
LMNA P02545 1/20 0.42
ANO1 Q5XXA6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29716784 1.00 P2RX4 (0.49) P2RX4CYP2C8CYP2D6CYP2C9ADRA2B
SCHEMBL28280467 0.90 LMNA (0.43) P2RX4CYP2C8CYP2D6CYP2C9ADRA2B
SCHEMBL19551527 0.90 P2RX4 (0.49) P2RX4CYP2C8CYP2D6CYP2C9ADRA2B
SCHEMBL19551847 0.90 P2RX4 (0.53) P2RX4CYP2C8CYP2D6CYP2C9ADRA2B
SCHEMBL29716978 0.90 P2RX4 (0.53) P2RX4CYP2C8CYP2D6CYP2C9ADRA2B
SCHEMBL19551788 0.90 CES2 (0.43) P2RX4CYP2C8CYP2D6CYP2C9ADRA2B
SCHEMBL19551742 0.90 P2RX4 (0.51) P2RX4CYP2C8CYP2D6CYP2C9ADRA2B
SCHEMBL29716850 0.88 P2RX4 (0.53) P2RX4CYP2C8CYP2D6CYP2C9ADRA2B
SCHEMBL19551730 0.88 P2RX4 (0.51) P2RX4LMNA
SCHEMBL19551591 0.88 P2RX4 (0.53) P2RX4CYP2C8CYP2D6CYP2C9ADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TAKASAKI UNIV OF HEALTH AND WELFARE (JP) 2026-01-01 US claimed
EP-4501357-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS Takasaki University of Health and Welfare (JP) 2025-02-05 EP claimed
CN-115054600-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-06-14 CN claimed
WO-2023190826-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS 学校法人 高崎健康福祉大学 2023-10-05 WO claimed
US-11524938-B2 Aromatic sulfonamide derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-12-13 US claimed
US-20220324807-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-10-13 US claimed
CN-115054600-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-09-16 CN claimed
CN-114984003-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-09-02 CN claimed
CN-109415321-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-06-17 CN claimed
US-10844016-B2 Aromatic sulfonamide derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-11-24 US claimed
EP-3458443-B1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma AG (DE) 2020-08-19 EP claimed
US-20190119210-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-04-25 US claimed
EP-3458443-A1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2019-03-27 EP claimed
WO-2017191000-A9 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-12-27 WO claimed
WO-2017191000-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-09 WO claimed
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TAKASAKI UNIV OF HEALTH AND WELFARE (JP) 2026-01-01 US disclosed
EP-4501357-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS Takasaki University of Health and Welfare (JP) 2025-02-05 EP disclosed
US-20190119210-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-04-25 US disclosed
CN-109415321-A aromatic sulfonamide derivatives 拜耳制药股份公司 2019-03-01 CN disclosed
WO-2017191000-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119210-A1 AROMATIC SULFONAMIDE DERIVATIVES ARSA, SULT2A1, TPST2 P2RX4 758/4885CYP2C8 35/4885CYP2D6 25/4885
US-20220324807-A1 AROMATIC SULFONAMIDE DERIVATIVES ARSA, SULT2A1, TPST2 P2RX4 758/4885CYP2C8 35/4885CYP2D6 25/4885
US-11524938-B2 Aromatic sulfonamide derivatives ARSA, SULT2A1, TPST2 P2RX4 758/4885CYP2C8 35/4885CYP2D6 25/4885
US-10844016-B2 Aromatic sulfonamide derivatives ARSA, SULT2A1, TPST2 P2RX4 758/4885CYP2C8 35/4885CYP2D6 25/4885
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TRPV1, TRPV4, TRPV5 P2RX4 15/4885CYP2C8 1265/4885CYP2D6 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.